Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

Technology Software - Application
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

NetraMark Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Post by waves1on Nov 09, 2021 3:00pm
134 Views
Post# 34106184

MEND on PurposeInvest's fund + CSO podcast & ALS research

MEND on PurposeInvest's fund + CSO podcast & ALS research
Few notable links on Nurosene Health Inc. ( $MEND $MEND.c ):
 
$MEND has the most portfolio weight in Bruce Campbell's @PurposeInvest small-cap fund.
https://twitter.com/AllStreetsWolf/status/1458138629339959298?s=20
 
CSO Dr. Geraci was featured on the I am a Mortal podcast regarding Nurosene and NetraMark, as well as how AI will shape the future of healthcare
https://open.spotify.com/show/1aX9zM67UVN5tv19v7GsDw?si=nVy0bg4zS0u2ZosF6R6NTw
 
Plus, Dr. Geraci is presenting his research on ALS at the EndALS Pitch Day hosted by a data science subsidiary of Google today. He was requested to help prepare genetic data to discover a set of new drug targets and repurpose candidates for ALS patients.
https://finance.yahoo.com/news/nurosenes-chief-scientific-officer-dr-140000074.html
 
$MEND is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments. As the global market size for mobile health applications (mHealth) is expected to reach USD $310 billion by 2027, $MEND has the ability to capitalize off its upcoming growth and is likely to do so.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities